News & Media
AMSTERDAM, NETHERLANDS – May 16th, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that a key patent covering its […]
AMSTERDAM, NETHERLANDS – February 20, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that […]
AMSTERDAM, NETHERLANDS – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that a key patent that encompasses the entire […]
20-22 September 2017
San Diego
26-27 September 2017
Basel
6-8 November 2017
Berlin
